for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lantheus Holdings Inc

LNTH.OQ

Latest Trade

18.82USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

16.31

 - 

29.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Progenics Pharmaceuticals Provides Update On Reconstituted Board's Ongoing Strategic Review

Jan 21 (Reuters) - Progenics Pharmaceuticals Inc <PGNX.O>::PROGENICS PHARMACEUTICALS PROVIDES UPDATE ON RECONSTITUTED BOARD’S ONGOING STRATEGIC REVIEW.PROGENICS PHARMACEUTICALS - BEEN CONDUCTING TWO SEPARATE REVIEWS TO EVALUATE PROPOSED LANTHEUS TRANSACTION.PROGENICS PHARMACEUTICALS - BEEN CONDUCTING TWO SEPARATE REVIEWS TO ALSO EVALUATE BUSINESS OPERATIONS AND STANDALONE PROSPECTS.PROGENICS PHARMACEUTICALS INC - CONTINUES TO REVIEW TRANSACTION WITH LANTHEUS.PROGENICS PHARMACEUTICALS INC - DUAL STRATEGIC REVIEWS ARE ACTIVELY ONGOING.

Lantheus Enters Into Strategic Collaboration With Carthera For Use Of Microbubbles In Combination With Sonocloud System For Treatment Of Glioblastoma

Dec 9 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS ENTERS INTO STRATEGIC COLLABORATION WITH CARTHERA FOR USE OF MICROBUBBLES IN COMBINATION WITH SONOCLOUD® SYSTEM FOR TREATMENT OF GLIOBLASTOMA.LANTHEUS ENTERS INTO STRATEGIC COLLABORATION WITH CARTHERA FOR USE OF MICROBUBBLES IN COMBINATION WITH SONOCLOUD® SYSTEM FOR TREATMENT OF GLIOBLASTOMA.LANTHEUS HOLDINGS INC - AGREEMENT SUPPORTS LANTHEUS' MICROBUBBLE FRANCHISE GROWTH STRATEGY AND EXPANSION INTO ONCOLOGY.LANTHEUS - ENTERED STRATEGIC COMMERCIAL SUPPLY AGREEMENT WITH CARTHERA FOR USE OF LANTHEUS' MICROBUBBLES IN COMBINATION WITH SONOCLOUD.LANTHEUS HOLDINGS INC - WILL RECEIVE ROYALTIES ON SONOCLOUD KIT PRODUCT SALES UPON REGULATORY APPROVAL.

Lantheus Holdings Reports Q3 Earnings Per Share $0.12

Oct 31 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS HOLDINGS, INC. REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 ADJUSTED EARNINGS PER SHARE $0.28.Q3 GAAP EARNINGS PER SHARE $0.12.Q3 REVENUE $85.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $83.8 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $0.21 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $346 MILLION TO $350 MILLION.UPDATES 2019 FULL YEAR REVENUE AND ADJUSTED DILUTED EARNINGS PER SHARE GUIDANCE.SEES FY 2019 REVENUE $347 MILLION - $349 MILLION.SEES FY 2019 ADJUSTED FULLY DILUTED EPS $1.10 - $1.13.SEES FY 2019 REVENUE GROWTH 1.1% - 1.6%.FY2019 EARNINGS PER SHARE VIEW $1.10, REVENUE VIEW $348.8 MILLION -- REFINITIV IBES DATA.

Lantheus To Acquire Progenics In All-Stock Transaction

Oct 2 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS TO ACQUIRE PROGENICS TO FORM A LEADING PRECISION DIAGNOSTICS IMAGING AND THERAPEUTICS COMPANY.LANTHEUS HOLDINGS - PROGENICS SHAREHOLDERS TO RECEIVE 0.2502 SHARES OF LANTHEUS COMMON STOCK FOR EACH SHARE OF PROGENICS STOCK IN ALL-STOCK DEAL.LANTHEUS HOLDINGS INC - PROGENICS SHAREHOLDERS WILL RECEIVE 0.2502 SHARES OF LANTHEUS HOLDINGS STOCK FOR EACH SHARE OF PROGENICS STOCK.LANTHEUS HOLDINGS INC - EXCHANGE RATIO REPRESENTS 35% AGGREGATE OWNERSHIP STAKE IN COMBINED COMPANY.LANTHEUS HOLDINGS INC - DEAL INTENDED TO BE TAX-FREE TO PROGENICS' STOCKHOLDERS FOR U.S. FEDERAL INCOME TAX PURPOSES.LANTHEUS HOLDINGS INC - COMBINED COMPANY WILL BE LED BY LANTHEUS CHIEF EXECUTIVE OFFICER MARY ANNE HEINO.LANTHEUS HOLDINGS INC - COMBINED COMPANY WILL TRADE ON NASDAQ UNDER TICKER SYMBOL: LNTH.LANTHEUS HOLDINGS INC - EXPECTS TO GENERATE APPROXIMATELY $15 TO $20 MILLION IN RUN-RATE COST SAVINGS BY 2022 FROM DEAL.LANTHEUS HOLDINGS - TRANSACTION EXPECTED TO ENHANCE CO'S CASH FLOW GENERATION & BE ACCRETIVE TO ADJUSTED & REPORTED EPS BY 2022 AND 2023, RESPECTIVELY.

Lantheus Holdings Q2 Adjusted Earnings Per Share $0.27

July 25 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS HOLDINGS, INC. REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $0.27.Q2 REVENUE $85.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $88.7 MILLION.Q2 GAAP EARNINGS PER SHARE $0.16.Q2 EARNINGS PER SHARE ESTIMATE $0.27 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE GROWTH 0.8% - 1.9%.SEES FY 2019 REVENUE $346 MILLION - $350 MILLION.SEES FY 2019 ADJUSTED FULLY DILUTED EPS $1.09 - $1.12.SEES Q3 FY 2019 REVENUE GROWTH (4.4)% - (6.6)%.SEES Q3 FY 2019 REVENUE $83 MILLION - $85 MILLION.SEES Q3 FY 2019 ADJUSTED FULLY DILUTED EPS $0.18 - $0.20.FY2019 EARNINGS PER SHARE VIEW $1.16 -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $360.2 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $0.29 -- REFINITIV IBES DATA.Q3 REVENUE VIEW $90.6 MILLION -- REFINITIV IBES DATA.LANTHEUS HOLDINGS - DURING QUARTER, COMPLETED AN ACCRETIVE REFINANCING OF ITS CREDIT FACILITY & EXPENSED $3.2 MILLION, PRE-TAX, OF DEBT EXTINGUISHMENT COSTS.LANTHEUS HOLDINGS - GUIDANCE FOR Q3 & FY 2019 INCORPORATE DAMPENING EFFECTS OF TEMPORARY MOLY SUPPLY ISSUES THAT OCCURRED IN Q2, CONTINUING INTO Q3.

Lantheus Holdings' Unit Refinanced Its Existing Indebtedness With New Term Loan Facility

July 1 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS HOLDINGS INC - ON JUNE 27, CO'S UNIT REFINANCED ITS EXISTING INDEBTEDNESS WITH NEW TERM LOAN FACILITY AND A NEW REVOLVING CREDIT FACILITY.LANTHEUS HOLDINGS INC - CREDIT AGREEMENT REPLACES THE OLD TERM FACILITY WITH A NEW FIVE-YEAR $200.0 MILLION TERM LOAN FACILITY.LANTHEUS HOLDINGS INC - CREDIT AGREEMENT REPLACES THE OLD REVOLVING FACILITY WITH A NEW $200.0 MILLION FIVE-YEAR REVOLVING CREDIT FACILITY.

Lantheus Announces Strategic Collaboration With Nanomab

May 30 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS ANNOUNCES STRATEGIC COLLABORATION WITH NANOMAB TO PROVIDE A NOVEL BIOMARKER FOR CLINICAL DEVELOPMENT AND MANAGEMENT OF IMMUNO-ONCOLOGY THERAPIES.LANTHEUS HOLDINGS INC - UNDER COLLABORATION AGREEMENT, LANTHEUS WILL LICENSE NANOMAB'S NM-01.LANTHEUS HOLDINGS INC - NANOMAB PLANS TO FILE AN INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER IN UNITED KINGDOM IN SECOND HALF OF 2019 FOR NM-01.

Lantheus Holdings Q1 GAAP Earnings Per Share $0.25

Lantheus Holdings Inc <LNTH.O>::LANTHEUS HOLDINGS, INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.28.Q1 GAAP EARNINGS PER SHARE $0.25.Q1 REVENUE $86.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $86.5 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.25 -- REFINITIV IBES DATA.SEES Q2 FY 2019 REVENUE GROWTH 0.5% - 5.2%.SEES Q2 REVENUE $86 MILLION - $90 MILLION.SEES Q2 ADJUSTED DILUTED EPS $0.23 - $0.28.SEES FY 2019 REVENUE GROWTH 4.25% - 5.75%.SEES FY 2019 REVENUE $358 MILLION - $363 MILLION.SEES FY 2019 ADJUSTED DILUTED EPS $1.14 - $1.17.FY2019 EARNINGS PER SHARE VIEW $1.16, REVENUE VIEW $360.8 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $0.30, REVENUE VIEW $90.6 MILLION -- REFINITIV IBES DATA.

Lantheus Enters Strategic Collaboration With Cerevast For Potential New Eye Care Application Using Microbubbles

April 2 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS ENTERS STRATEGIC COLLABORATION WITH CEREVAST FOR POTENTIAL NEW EYE CARE APPLICATION USING MICROBUBBLES.LANTHEUS HOLDINGS INC - AS PART OF AGREEMENT, CEREVAST WILL BE RESPONSIBLE FOR REGULATORY FILINGS AND APPROVALS IN U.S., EUROPE AND CHINA.LANTHEUS HOLDINGS INC - LANTHEUS WILL SUPPLY ITS MICROBUBBLE VIALS AND ITS ACTIVATION DEVICES AT A PREDETERMINED TRANSFER PRICE.LANTHEUS HOLDINGS INC - LANTHEUS WILL RECEIVE ROYALTIES ON SALES OF RVO TECHNOLOGY AFTER REGULATORY APPROVAL.

Lantheus Holdings Sees 2019 Adjusted Diluted EPS $1.14 - $1.17

Feb 19 (Reuters) - Lantheus Holdings Inc <LNTH.O>::LANTHEUS HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 REVENUE $86.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $83.7 MILLION.SEES 2019 ADJUSTED DILUTED EPS $1.14 - $1.17.SEES FY 2019 REVENUE $358 MILLION - $363 MILLION.SEES Q1 FY 2019 ADJUSTED DILUTED EPS $0.23 - $0.25.SEES Q1 2019 REVENUE $85 MILLION - $87.5 MILLION.FY2019 EARNINGS PER SHARE VIEW $0.96, REVENUE VIEW $361.5 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.24, REVENUE VIEW $88.5 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up